Hospital
Mayo Clinic Health System-Northwest Wisconsin Region, INC.
Mayo Clinic Health System-Northwest Wisconsin Region, INC. was paid $9.93M by Medicaid between Jan 2018 and Dec 2024, across 181 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 15% of everything it billed.
33Billing provider infoMAYO CLINIC HEALTH SYSTEM-NORTHWEST WISCONSIN REGION, INC.
MENOMONIE, WI 54751
MENOMONIE, WI 54751
33aNPI1154372944assigned 05/15/2006
33bProvider typeCritical Access Hospital
28Total paid$9.93M
24GClaims344,497
24DCodes billed181
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Wisconsin
Rank by total paid#7 of 48
Median peer was paid$4.30M
This provider vs. median2.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BORTNEM, MARK controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 46,475 | $943K | |
| 2019 | 44,363 | $1.18M | |
| 2020 | 41,647 | $1.15M | |
| 2021 | 56,351 | $1.57M | |
| 2022 | 52,451 | $1.70M | |
| 2023 | 55,561 | $1.93M | |
| 2024incomplete | 47,649 | $1.46M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 15% | 3,919 | 3,281 | $1.49M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 10,939 | 7,238 | $1.37M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 6,960 | 5,475 | $1.14M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.9% | 8,339 | 5,925 | $985K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 5.1% | 21,581 | 16,502 | $505K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.4% | 2,092 | 1,795 | $438K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.3% | 2,110 | 1,850 | $430K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.2% | 1,795 | 1,615 | $314K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.8% | 12,783 | 5,481 | $283K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.7% | 1,668 | 1,209 | $269K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.3% | 1,046 | 951 | $225K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.6% | 14,332 | 10,126 | $159K |
169 more codes
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.2% | 4,101 | $118K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.1% | 3,807 | $105K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 20,931 | $90K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 9,807 | $81K |
| 80053 | Comprehensive metabolic panel | <1% | 11,220 | $80K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,284 | $79K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,697 | $78K |
| 87631 | <1% | 812 | $69K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,623 | $68K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,865 | $65K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,313 | $64K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 901 | $58K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,473 | $56K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 4,600 | $54K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 234 | $51K |
| 97162 | <1% | 1,717 | $51K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,524 | $48K |
| 80061 | Lipid panel | <1% | 5,202 | $47K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 630 | $41K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,682 | $39K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 130 | $39K |
| 87480 | <1% | 2,597 | $39K | |
| 87660 | <1% | 2,597 | $38K | |
| 87510 | <1% | 2,597 | $38K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 161 | $37K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,326 | $36K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,169 | $34K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,141 | $33K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 174 | $33K |
| 73630 | <1% | 1,068 | $29K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 439 | $28K |
| 97161 | <1% | 753 | $28K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 446 | $26K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 51 | $26K |
| 81025 | <1% | 4,119 | $26K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 124 | $23K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,791 | $22K |
| 84484 | <1% | 2,855 | $22K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 653 | $21K |
| 83605 | <1% | 3,481 | $20K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,245 | $18K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,799 | $18K |
| 80306 | <1% | 1,283 | $17K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,262 | $15K |
| 81001 | <1% | 6,976 | $14K | |
| 83690 | <1% | 3,405 | $14K | |
| 85610 | <1% | 6,115 | $12K | |
| 80050 | General health panel | <1% | 444 | $12K |
| 83880 | <1% | 929 | $11K | |
| 83735 | <1% | 3,005 | $11K | |
| 90837 | Psychotherapy session, about an hour | <1% | 153 | $10K |
| 82077 | <1% | 1,127 | $9K | |
| 76830 | Ultrasound, transvaginal | <1% | 113 | $9K |
| 82728 | <1% | 883 | $9K | |
| 85027 | <1% | 2,238 | $9K | |
| 86140 | <1% | 2,757 | $9K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 133 | $9K |
| 87103 | <1% | 1,117 | $8K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,524 | $8K |
| 87040 | <1% | 2,111 | $7K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,479 | $7K |
| 81003 | <1% | 4,464 | $7K | |
| 82947 | <1% | 2,469 | $7K | |
| 85379 | <1% | 1,087 | $6K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 114 | $6K |
| 82570 | <1% | 1,929 | $6K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 180 | $5K |
| 84702 | <1% | 467 | $5K | |
| 82043 | <1% | 1,573 | $5K | |
| 82565 | <1% | 1,589 | $5K | |
| 73610 | <1% | 273 | $5K | |
| 73030 | <1% | 209 | $5K | |
| 82803 | <1% | 416 | $5K | |
| 86850 | <1% | 1,436 | $5K | |
| 80143 | <1% | 424 | $4K | |
| 82948 | <1% | 1,630 | $4K | |
| 80179 | <1% | 373 | $4K | |
| 82248 | <1% | 1,421 | $4K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 250 | $3K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,515 | $3K |
| 73564 | <1% | 184 | $3K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 119 | $3K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 417 | $3K |
| 87077 | <1% | 1,041 | $3K | |
| 85018 | <1% | 1,590 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 14,565 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 761 | $2K |
| 97597 | <1% | 154 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 102 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 102 | $2K |
| 90715 | <1% | 149 | $2K | |
| 84460 | <1% | 572 | $2K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 24 | $2K |
| 87186 | <1% | 826 | $2K | |
| 93976 | <1% | 22 | $2K | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 644 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,336 | $2K |
| 84450 | <1% | 437 | $1K | |
| Q3014 | Telehealth originating site facility fee | <1% | 345 | $1K |
| 86901 | <1% | 772 | $1K | |
| 86900 | <1% | 772 | $1K | |
| 99442 | <1% | 98 | $1K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 18 | $1K |
| 88142 | <1% | 39 | $970.47 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,231 | $943.46 |
| 91322 | <1% | 169 | $911.32 | |
| 83550 | <1% | 158 | $821.42 | |
| 83540 | <1% | 182 | $699.19 | |
| 72100 | <1% | 19 | $689.57 | |
| 36416 | <1% | 2,722 | $686.25 | |
| 90686 | <1% | 602 | $608.14 | |
| 99443 | <1% | 34 | $592.27 | |
| 73110 | <1% | 16 | $586.15 | |
| 73502 | <1% | 30 | $484.38 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 12 | $459.60 |
| 90662 | <1% | 445 | $428.48 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 62 | $428.13 |
| 83655 | <1% | 27 | $391.99 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,046 | $384.54 |
| 84550 | <1% | 160 | $365.11 | |
| 73562 | <1% | 16 | $340.63 | |
| 73080 | <1% | 13 | $326.41 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,423 | $288.60 |
| 90480 | <1% | 165 | $264.10 | |
| 93971 | <1% | 17 | $192.99 | |
| 85652 | <1% | 99 | $180.42 | |
| 82950 | <1% | 39 | $173.90 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 988 | $92.19 |
| 0764T | <1% | 186 | $76.08 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,007 | $74.08 |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 173 | $73.13 |
| 84439 | <1% | 12 | $70.14 | |
| 84132 | <1% | 30 | $69.57 | |
| 86308 | <1% | 15 | $54.06 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 18 | $51.58 |
| 0004A | <1% | 33 | $50.31 | |
| 84156 | <1% | 15 | $45.89 | |
| 90656 | <1% | 36 | $41.55 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 233 | $34.74 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 421 | $33.66 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 785 | $13.30 |
| 90677 | <1% | 59 | $13.23 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 32 | $11.64 |
| J3490 | Unclassified drugs | <1% | 292 | $10.47 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 14 | $10.08 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 292 | $9.33 |
| 0064A | <1% | 31 | $4.05 | |
| J2704 | Injection, propofol, 10 mg | <1% | 29 | $3.81 |
| 0124A | <1% | 58 | $3.69 | |
| 0054A | <1% | 60 | $1.95 | |
| A9270 | Non-covered item or service | 0% | 1,792 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 880 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 32 | $0.00 |
| 92136 | 0% | 13 | $0.00 | |
| 96376 | 0% | 60 | $0.00 | |
| 93000 | 0% | 16 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 38 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 15 | $0.00 |
| G0009 | Administration of pneumococcal vaccine | 0% | 39 | $0.00 |
| 87070 | 0% | 27 | $0.00 | |
| 0134A | 0% | 19 | $0.00 | |
| 00142 | 0% | 27 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 21 | $0.00 |
| J0697 | Injection, sterile cefuroxime sodium, per 750 mg | 0% | 12 | $0.00 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 69 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 110 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 49 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 93 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBORTNEM, MARK (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.